Scientific Initiatives, Stock Price Movement, and Financial Results - Research Report on BMS, Actavis, LabCorp, Quest Diagnostics, and Novartis PR Newswire NEW YORK, October 23, 2013 NEW YORK, October 23, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Co. (NYSE: BMY), Actavis plc (NYSE: ACT), Laboratory Corp. of America Holdings (NYSE: LH), Quest Diagnostics Inc. (NYSE: DGX), and Novartis AG (ADR) (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Bristol-Myers Squibb Co. Research Report On October 16, 2013, Bristol-Myers Squibb Co. (BMS) announced the launch of Partnering for Cure, a scientific initiative to support education and research to transform clinical outcomes for patients with chronic viral diseases, such as HIV, hepatitis B (HBV), and hepatitis C (HCV). The announcement came in at the 14th European AIDS Conference (EACS) in Brussels, Belgium. The Company said that Partnering for Cure is led by an expert panel of clinical experts from across Europe. It will be composed of three core components (education, scientific exchange, and scientific research) and will focus on reviewing current treatment paradigms, providing a forum for discussion on the evolution of treatment towards cure and facilitating research seeking novel cure pathways in chronic viral diseases. BMS reported that it will also support three independent research projects focused on improving current understandings of HIV, HBV and HCV, and creating novel treatment and cure strategies, and the research applications will be accepted via the Company website until October 31, 2013. The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/81a9_BMY] -- Actavis plc Research Report On October 18, 2013, Actavis plc's (Actavis) stock rose marginally by 0.03%, ending the day at $146.92. Over the previous three trading sessions, shares of Actavis gained 4.54%, outperforming the S&P 500, which gained 2.73% during the same period. The Full Research Report on Actavis plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT] -- Laboratory Corp. of America Holdings Research Report On October 18, 2013, Laboratory Corp. of America Holdings (LabCorp) reported its Q3 2013 financial results. The Company's net sales increased 3.0% YoY to $1.5 billion during the quarter. Net earnings attributable to LabCorp were $148.3 million or $1.63 per diluted share in Q3 2013, compared to net earnings attributable to LabCorp of $148.0 million or $1.53 per diluted share in Q3 2012. Adjusted EPS excluding amortization increased 2.3% YoY to $1.80. David P. King, Chairman and CEO of LabCorp, said, "We are pleased with our third quarter and year-to-date results, as we delivered another quarter of solid revenue and volume growth. Government payment reductions and continued reimbursement challenges for molecular testing negatively affected our reported results in terms of revenue growth, price and margins. Despite these challenges, we continue to execute our five pillar strategy and remain focused on growing our business and returning capital to shareholders." The Full Research Report on Laboratory Corp. of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c267_LH] -- Quest Diagnostics Inc. Research Report On October 17, 2013, Quest Diagnostics, Inc. (Quest Diagnostics) reported its Q3 2013 financial results. The Company's net revenues declined 1.9% YoY to $1.8 billion during the quarter. Net income attributable to Quest Diagnostics was $405.1 million or $2.68 per diluted share in Q3 2013, up compared to net income attributable to Quest Diagnostics of $163.1 million or $1.01 per diluted share in Q3 2012. Commenting on the results, Steve Rusckowski, President and CEO of Quest Diagnostics, said, "We are disappointed with our third quarter performance, particularly after generating revenues early in the period that were in line with our expectations. Healthcare utilization and reimbursement continue to be a headwind for our industry, and our results reflect that. As we have said previously, 2013 is a building year that will position us well for 2014 and beyond. We remain focused on executing our five-point strategy." The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05ba_DGX] -- Novartis AG (ADR) Research Report On October 18, 2013, Bloomberg reported that Roche Holding AG's (Roche) CEO Severin Schwan said that founding families of Roche wants the Company to stay independent, in response to the speculation that circulated since a Novartis AG (ADR) (Novartis) board member Pierre Landolt said in September 2013 that a merger could make sense. The Bloomberg report also quoted what Schwan said in a conference call with reporters, "Nothing has changed with regards to Roche's position towards Novartis. The families Hoffmann and Oeri have repeatedly stated they're committed to Roche's independence." The Full Research Report on Novartis AG (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6d_NVS] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Scientific Initiatives, Stock Price Movement, and Financial Results - Research Report on BMS, Actavis, LabCorp, Quest
Press spacebar to pause and continue. Press esc to stop.